KEZAR LIFE SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7895 USD | +5.62% |
|
-6.01% | -16.67% |
Presenter SpeechSteve Tuekam (Analysts)Good afternoon, everyone, and thank you for joining us ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Calendar
2024-06-18
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.7895
USD
Average target price
11.67
USD
Spread / Average Target
+1,377.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.67% | 54.42M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- KZR Stock
- News Kezar Life Sciences, Inc.
- Transcript : Kezar Life Sciences, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 02